215 Church Street
New Haven, CT 06510


General Information:

Biohaven Ltd. (NYSE: BHVN) is a global clinical-stage biopharmaceutical company and a recognized industry leader in scientific innovation and drug development. The company initially focused on advancing novel treatments in neuroscience but has expanded its efforts to pursue innovative and potentially life-changing therapies for people suffering from a range of debilitating diseases, including common and rare disorders, that have limited or no treatment options. Biohaven is leveraging its proven drug development capabilities and proprietary platforms to advance new investigational drugs in areas including immunology and inflammatory disorders, obesity,  and oncology.

Biohaven has advanced a deep pipeline of early- and late-stage product candidates across multiple high-value platforms including: Kv7 ion channel modulation for epilepsy, depression and neuronal hyperexcitability; TRPM3 channel activation for neuropathic pain; targeted extracellular protein degradation for autoimmune disorders; glutamate modulation for obsessive-compulsive disorder; myostatin inhibition for neuromuscular diseases and metabolic disorders; brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders; and next-generation bispecific technologies for ADCs in oncology.

As a modern biopharmaceutical company with an agile operating model and a decentralized, entrepreneurial structure, Biohaven’s operational excellence is the engine of its skillful clinical execution and efficiency, that propels our ability to advance transformative new medicines to waiting patients. It’s why we use the phrase “Days Matter” at Biohaven because it underlies our commitment to making each day count for waiting patients.